APP and Alzheimer disease: Starting from data reported in the literature that showed the ability of punicalagin to decrease NFAT activity in vitro [96] and considering that both punicalagin and EA after oral ingestion are available in plasma, the researchers studied if the PE and its mentioned isolated components had any inhibitory activity in vitro on NFAT or in vivo on the amyloid precursor protein/presenilin 1 (APP/PS1) transgenic AD mouse model [84].